Skip to main content
Ethan J. Zausner

Ethan J. Zausner

Senior Associate

Ethan Zausner's practice focuses on corporate transactions, including mergers and acquisitions, private equity investments, licensing and collaboration agreements, and securities offerings.

Mr. Zausner received his JD from Fordham Law School, where he was a Notes and Articles Editor for the Intellectual Property, Media & Entertainment Law Journal.


  • Pfizer, on an asset purchase and license agreement for a portfolio of preclinical gene therapy programmes and enabling technologies with Alexion, AstraZeneca Rare Disease, for up to US$1 billion.
  • Novartis, on its acquisition of clinical candidate FAP-2286 from Clovis Oncology, for an upfront payment of $50 million and up to an additional $630.75 million on the achievement of certain regulatory and sales milestones.
  • Private equity fund DC Capital Partners and its portfolio companies in acquisition and sale transactions.
  • The Halifax Group in its investment in TriMech, a leading provider of engineering design solutions.
  • VitreoRetinal Surgery in a sale transaction and entry into practice management arrangements with a portfolio company of a private equity buyer.
  • USI Insurance Services in various acquisitions, including its acquisition of Associated Financial Group, an insurance brokerage, from Associated Bank, a subsidiary of Associated Banc-Corp (ABRC), for $266 million in cash (subject to certain adjustments).
  • AT&T in connection with merger control matters related to Discovery’s $43 billion purchase of WarnerMedia from AT&T.
  • BrightSpring Health Services (formerly ResCare), an Onex portfolio company and the leading provider of comprehensive home and community-based health services to complex populations in need of specialized care, in its sale to affiliates of KKR.
  • Onex Corporation in the sale of USI Insurance Services to an affiliate of KKR & Co. L.P. and Caisse de dépôt et placement du Québec for an enterprise value of $4.3 billion.
  • Pharmachem Laboratories, a leading provider of quality ingredients to the global health and wellness industries, on its sale to Ashland, a global leader in providing specialty chemical solutions.
  • Life sciences and pharmaceutical companies in licensing, acquisition and sale transactions.
  • Pfizer Inc. in its acquisition of Therachon Holding AG, a clinical-stage biotechnology firm focusing on rare diseases.



  • J.D., Fordham University School of Law, 2016
  • B.B.A., The George Washington University, 2013


  • New York